A homocysteine blood test measures a single amino acid byproduct that builds up when B12, folate, or B6 metabolism isn't keeping pace. A result under 15 micromol/L is normal; above that, most labs flag it as elevated, and the higher it climbs past 30 or 100 micromol/L, the more urgently it needs a workup rather than a supplement bottle. The number by itself doesn't tell you much — it only means something once a clinician reads it next to your kidney function, thyroid status, and the rest of your cardiovascular labs.
TL;DR
- A homocysteine blood test above 15 micromol/L is mildly elevated; above 30 is moderate; above 100 is severe, per standard 2026 clinical reference ranges.
- B12, folate, and B6 deficiency cause most elevated homocysteine results, not dietary fat or LDL cholesterol.
- High homocysteine tracks with cardiovascular and cognitive risk, but B-vitamin correction hasn't reliably cut heart attacks or strokes in major outcome trials.
- The MTHFR gene variant, chronic kidney disease, hypothyroidism, and smoking all push homocysteine up independent of vitamin status.
- GoodLife Health's clinicians read homocysteine alongside ApoB, Lp(a), and hs-CRP rather than treating it as a standalone verdict.
- Under 15 micromol/L is normal; 15-30 is mildly elevated; 30-100 is moderate; above 100 is severe.
- B12, folate, and B6 deficiency — not dietary fat or LDL cholesterol — drive most elevated results.
- High homocysteine correlates with cardiovascular and cognitive risk, but B-vitamin correction hasn't reliably reduced heart attacks or strokes.
- The MTHFR gene variant, chronic kidney disease, hypothyroidism, and smoking raise homocysteine independent of vitamin status.
- Mild or moderate elevations are typically retested 8-12 weeks after starting B-vitamin correction.
- GoodLife Health reads homocysteine alongside ApoB, Lp(a), and hs-CRP rather than as a standalone verdict.
Why this matters
Homocysteine got attention in cardiology decades before ApoB or Lp(a) became standard vocabulary, and it still gets ordered inconsistently in 2026 — some primary care visits never touch it unless a patient specifically asks. That's a gap, because homocysteine sits at the intersection of methylation, kidney function, thyroid status, and cardiovascular risk, exactly the kind of interconnected system GoodLife Health treats as one problem rather than four separate specialists' worth of appointments.
A single elevated number rarely means a crisis. It usually means something upstream — a vitamin gap, a kidney marker drifting, a thyroid slowing down — is worth chasing before it compounds into something bigger. Treat homocysteine as a clue, not a diagnosis.
A single elevated number rarely means a crisis. It usually means something upstream — a vitamin gap, a kidney marker drifting, a thyroid slowing down — is worth chasing before it compounds into something bigger. Treat homocysteine as a clue, not a diagnosis.
What does a homocysteine blood test measure?
The test itself is a simple fasting blood draw. Most labs want you fasted for 10-12 hours because recent protein intake can nudge the number temporarily. The result gets classified into four bands that determine what happens next.
Homocysteine Result Ranges
micromol/L
| Range (micromol/L) | Classification | What it usually means |
|---|---|---|
| Under 15 | Normal | Methylation and B-vitamin metabolism functioning as expected |
| 15-30 | Mildly elevated | Common; often a correctable B12, folate, or B6 gap |
| 30-100 | Moderately elevated | Kidney impairment, an MTHFR variant, or a more significant deficiency |
| Above 100 | Severely elevated | Rare, often inherited enzyme disorders; needs specialist referral |
The test doesn't diagnose a specific disease on its own. It's a marker that gets paired with other labs — an ApoB lab test for particle count, a comprehensive metabolic panel for kidney function, and a thyroid panel — before a clinician decides whether the number is a footnote or a flag.
Mild elevation: 15-30 micromol/L
This is the band most people land in when they first test, and it's rarely alarming on its own. The most common driver at this level is a B12, folate, or B6 intake gap, sometimes from a diet low in leafy greens and animal protein, sometimes from a medication like metformin that interferes with B12 absorption over years of use.
Correction is usually straightforward: methylfolate, B12, and B6 supplementation, followed by a retest in 8-12 weeks. Verdict: buy time with correction and retest, don't escalate to specialist care yet unless the number climbs on repeat testing.
Moderate elevation: 30-100 micromol/L
This range needs more than a vitamin bottle. It's where clinicians start checking kidney function seriously, screening for the MTHFR gene variant, and ruling out untreated hypothyroidism, because any of the three can push homocysteine into this zone even with adequate vitamin intake.
Patients in this band often have a second abnormal marker sitting alongside it — reduced kidney filtration, an elevated TSH, or a low B12 despite supplementation, which points to an absorption problem rather than an intake problem. Verdict: this range needs a physician-guided workup, not self-directed supplementation.
Severe elevation: above 100 micromol/L
This is uncommon and usually points to something more specific than diet: a rare inherited enzyme disorder like homocystinuria, severe untreated vitamin deficiency, or advanced kidney disease. It's associated with a meaningfully higher risk of blood clots and early vascular disease when left unaddressed.
Verdict: severe elevation needs a specialist referral, not a repeat test in three months. This is the one band where waiting costs more than acting.
It's associated with a meaningfully higher risk of blood clots and early vascular disease when left unaddressed. Severe elevation needs a specialist referral, not a repeat test in three months — this is the one band where waiting costs more than acting.
Why homocysteine levels vary
Six factors drive most of the variation clinicians see on this marker:
- B12, folate, and B6 status — the direct inputs the body uses to clear homocysteine
- The MTHFR gene variant — a common inherited enzyme change that slows how efficiently the body processes folate
- Kidney function — declining filtration reduces homocysteine clearance regardless of vitamin intake
- Thyroid status — untreated hypothyroidism is a known, reversible driver of elevated results
- Smoking — associated with higher homocysteine independent of diet
- Certain medications — methotrexate, some anticonvulsants, and long-term metformin use can all raise the number
Age plays a role too: homocysteine tends to climb gradually after the 50s, which is part of why it shows up more often on labs for patients being evaluated for hormone optimization for men over 50 than for people in their 30s.
Who should ask for a homocysteine test
Most annual physicals skip this test unless a patient specifically requests it, which is a gap worth closing in a few specific situations. A family history of early heart attack or stroke, unexplained blood clots, recurrent pregnancy loss, or symptoms of B12 deficiency — fatigue, tingling in the hands or feet, memory changes — are all reasonable triggers to ask a clinician to order it.
It's also a reasonable add-on for anyone already getting a broader cardiovascular workup. Patients checking a Lp(a) blood test for inherited cholesterol risk are often good candidates for homocysteine at the same draw, since both are inherited-risk markers that a standard lipid panel misses entirely.
Is a homocysteine test the same as a lipid panel?
No. A homocysteine test measures an amino acid byproduct tied to B-vitamin metabolism and inherited enzyme function; a lipid panel measures cholesterol particles like LDL, HDL, and triglycerides. They flag different risk pathways and neither substitutes for the other.
A complete cardiovascular risk picture in 2026 typically pulls both, plus ApoB and Lp(a), because a patient can have a pristine lipid panel and still carry elevated homocysteine or Lp(a) driving risk the standard cholesterol numbers never catch.
Does high homocysteine cause heart disease, or just correlate with it?
High homocysteine correlates strongly with cardiovascular disease and stroke risk, but the causal link is weaker than the correlation suggests. Large outcome trials from the early 2000s — HOPE-2 and VISP among them — showed that B-vitamin supplementation reliably lowers homocysteine but doesn't consistently reduce heart attacks or strokes.
That gap matters clinically: a clinician treats an elevated result as one input into overall risk, not as a marker that guarantees disease if left untreated or guarantees safety once corrected.
A clinician treats an elevated result as one input into overall risk, not as a marker that guarantees disease if left untreated or guarantees safety once corrected.
Can B vitamins lower homocysteine, and does that lower disease risk?
Yes, B vitamins lower the number. Methylfolate, B12, and B6 supplementation typically bring an elevated homocysteine result down within weeks, and that part of the equation is well established. What's less certain is whether correcting the number on its own reduces cardiovascular events — the trial evidence for that leap is mixed, which is why physicians treat vitamin correction as fixing a metabolic input, not curing a disease.
The same B12 and folate gap that drives homocysteine up shows up disproportionately in patients dealing with low mood and depression, and that overlap deserves its own attention rather than getting filed under "just take a vitamin." Patients working through both a biomarker problem and a mood problem tend to do better pairing the lab correction with structured behavioral work, and pairing clinical care with self-help resources for depression that address sleep, movement, and thought patterns alongside the vitamin fix tends to move both numbers and mood faster than either approach alone.
F
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/